Lupin Q1 FY27 Results: Sales Surge 33% YoY to ₹82,172 Crore, EBITDA Up 50%
Lupin Limited reported Q1 FY27 results with net sales surging 33.3% YoY to ₹82,172 crore. EBITDA grew 50.1% to ₹2,463.5 crore, with margins at 30.0%. Net income rose 16.1% to ₹1,415 crore. Key drivers included strong growth in North America and India, along with new product launches and regulatory approvals.
The significant increase in sales and profitability, coupled with positive operational developments such as product approvals and R&D pipeline advancements, are expected to have a material positive impact on the company's financial performance and market position.
The company reported strong year-on-year growth in sales and EBITDA, improved margins, and a rise in net income. Several positive regulatory approvals and product launches were also highlighted, indicating strong operational performance and a positive outlook.
Lupin Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting a significant 33.3% year-on-year increase in net sales to ₹82,172 million (₹8,217.2 crore). The company's EBITDA also saw a substantial rise of 50.1% to ₹24,635 million (₹2,463.5 crore), with EBITDA margins improving to 30.0% from 26.6% in the prior year period.
Net income for the quarter stood at ₹14,150 million (₹1,415 crore), an increase of 16.1% year-on-year. The company highlighted strong performance across key geographies, with North America sales growing by 43% YoY to ₹35,908 million, India sales up 14% YoY to ₹23,796 million, and Europe, Middle East and Africa (EMEA) sales increasing by 37% YoY to ₹8,602 million.
Key developments during the quarter included regulatory approvals for its Nagpur Unit I & II from HLfGP (Germany) and CDSCO approval for Ankleshwar. The company also received EMA approval to extend NaMuscla® for children and China approval for Oseltamivir Phosphate oral suspension. Lupin launched Luforbec® (beclometasone/formoterol) MDI in Spain and presented Phase 1a data for LNP8701 at ASCO 2026. The company also received US FDA Approval for Azilsartan Medoxomil Tabs and Ranibizumab (Ranluspec) biosimilar.
Lupin emphasized its commitment to quality and innovation, with successful FDA inspections at multiple sites and ongoing remediation efforts. The company is pivoting its R&D towards complex generics and biosimilars, aiming for multiple launches in regulated markets by 2028. Lupin also highlighted its robust sustainability initiatives and received recognition for its ESG performance, including a top ranking in the pharma sector globally.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.